famotidine has been researched along with Gastritis, Atrophic in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Gastritis, Atrophic: GASTRITIS with atrophy of the GASTRIC MUCOSA, the GASTRIC PARIETAL CELLS, and the mucosal glands leading to ACHLORHYDRIA. Atrophic gastritis usually progresses from chronic gastritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Famotidine was administered after lunch and before sleep, and the others were after breakfast and dinner." | 2.71 | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. ( Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M, 2005) |
| "The majority of gastro-oesophageal reflux disease (GERD) seems to be non-erosive reflux disease." | 1.33 | Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. ( Hiraishi, H; Masuyama, H; Nakamura, T; Shirakawa, K; Sugaya, H; Terano, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okudaira, K | 1 |
| Furuta, T | 1 |
| Shirai, N | 1 |
| Sugimoto, M | 1 |
| Miura, S | 1 |
| Nakamura, T | 1 |
| Shirakawa, K | 1 |
| Masuyama, H | 1 |
| Sugaya, H | 1 |
| Hiraishi, H | 1 |
| Terano, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for famotidine and Gastritis, Atrophic
| Article | Year |
|---|---|
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2005 |
1 other study available for famotidine and Gastritis, Atrophic
| Article | Year |
|---|---|
Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Bile; Color; Esophagitis; Esophagoscopy; Famotidine; Female; Gastrit | 2005 |